Elglustat is an oral targeted drug for the treatment of type 1 Gaucher disease, produced by Sanofi in France. The drug has not yet been launched in China, nor has it been included in the medical insurance, and there are currently no generic drugs available. During use, attention should be paid to cardiovascular risks, drug interactions, and contraindications for special populations.
How much does Elglustat cost per box?
Elglustat is a specific drug for Gaucher disease, and its price is relatively high, mainly due to its research and development costs and market exclusivity. Understanding its price information will help patients and their families make treatment plans.
Price and specifications Elglustat is produced by Sanofi in France, with a specification of 84mg*56 tablets/box. This price reflects its market positioning as a drug for rare diseases.
Since there are no generic drugs available, patients need to rely on imported original drugs, which further increases the economic burden of treatment.
Economic burden and solutions High drug prices put a lot of pressure on patients' families. Some countries have reduced the burden on patients through medical insurance or assistance programs, patients still need to purchase at their own expense or seek other support channels.
The price of Elglustat is related to its efficacy and rare disease characteristics. If it enters medical insurance or generic drugs in the future, it will greatly improve the accessibility of patients to drugs.
Indications of Elglustat
The indications of Elglustat are clear, mainly for patients with type 1 Gaucher disease with specific metabolic types. Understanding its indications helps to use drugs accurately.
Applicable population
Elglustat is suitable for adult type 1 Gaucher disease patients with CYP2D6 extensive metabolizer, intermediate metabolizer or poor metabolizer genotype. It is not recommended for patients with ultra-rapid metabolizers due to insufficient efficacy.
Pharmacological action
The drug inhibits glucosylceramide synthase and reduces the accumulation of characteristic substrates of Gaucher disease, thereby alleviating symptoms and delaying disease progression.
Dosage adjustment
The dose needs to be adjusted individually according to the patient's metabolic type. Patients with extensive metabolizers and intermediate metabolizers take it twice a day, and patients with poor metabolizers take it once a day. Further adjustments are required when combined medication or liver function is abnormal.
The indications and dosage regimen of Elglustat reflect the concept of precision medicine and provide effective treatment options for specific patients.
Contraindications of Elglustat
There are certain restrictions on the use of Elglustat, and some people need to prohibit or use it with caution. Clarifying contraindications is the prerequisite for medication.
Cardiovascular risks
Patients with a history of heart disease or congenital long QT syndrome are prohibited from using Elglustat because it may prolong the cardiac conduction interval and induce arrhythmias.
Restrictions on special populations
Children, pregnant women and breastfeeding women need to carefully assess the risks and benefits. Elderly people and patients with liver and kidney damage also need to adjust the medication regimen according to specific circumstances.
Drug interactions
Combined use with CYP2D6 or CYP3A inhibitors may lead to increased blood drug concentrations and increase the risk of adverse reactions. Strong CYP3A inducers may reduce efficacy and should be avoided in combination.
The contraindications of Elglustat indicate the complexity of medication, and patients need to strictly follow the medication specifications under the guidance of a doctor.
